Novartis’ Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
Pending regulatory submission, Fabhalta (iptacopan) could become the first approved therapy for C3G, addressing a significant unmet need in nephrology, according to Spherix Global Insights. EXTON, PA., June 13, 2024 – Complement 3 glomerulopathy (C3G) is a rare kidney disease that presents significant challenges for both patients and nephrologists. Currently, there are no therapies specifically […]
EU Nephrologists Foresee Travere/CSL Vifor’s FILSPARITM (sparsentan) Transforming IgA Nephropathy Treatment as the First Non-Immunosuppressive Therapy
Data from Spherix Global Insights’ second annual EU IgAN patient chart audit indicates that even with the EMA approval of FILSPARITM (sparsentan), opportunities for pipeline agents to make an impact remain. EXTON, PA., April 30, 2024 – Over the past several years, glomerular diseases have garnered significant attention from the nephrology industry, largely driven by […]
IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
Spherix Global Insights’ fourth annual IgAN patient chart audit reveals continued shifts in the IgAN treatment paradigm with the use of SGLT2 inhibitors, TARPEYO (Calliditas), and FILSPARI (Travere Therapeutics). EXTON, Pa., March 12, 2024 – The past several years have brought a transformative shift to the IgA nephropathy (IgAN) treatment landscape, including the introduction of […]
Chart review shows nephrologists prescribing more SGLT2 inhibitors
A chart review completed by Spherix Global Insights shows that more nephrologists are using SGLT2 inhibitors to treat patients with chronic kidney disease, according to a press release. “Analysis of 1,052 chronic kidney disease non-dialysis patient charts reveals continuous growth in SGLT2 inhibitor use and expanding opportunities for [mineralocorticoid receptor agonists] MRAs and [glucagon-like peptide-1] […]
Use of SGLT2 Inhibitors Continues to Expand for the Treatment of Chronic Kidney Disease, with Eli Lilly/Boehringer Ingelheim’s Jardiance Making Significant Strides Following Label Expansion
Analysis of 1,052 chronic kidney disease non-dialysis patient charts reveals continuous growth in SGLT2 inhibitor use and expanding opportunities for MRAs and GLP-1s, according to Spherix Global Insights. EXTON, Pa., Jan 03, 2024 – Since 2019, audited records of chronic kidney disease (CKD) non-dialysis patients has revealed an ongoing, annual uptick in the proportion […]
FibroGen/Astellas’ EVRENZO (roxadustat) Making In-Roads in European Market as In-Class Challenger, Akebia/Medice’s VAFSEO (vadadustat), Prepares for Launch in Early 2024.
EVRENZO’s advantages of being first-to-market and possessing a broader label are likely to be key factors influencing VAFSEO uptake, according to the latest update from Spherix Global Insights. [Exton, PA., December 8, 2023]– EVRENZO made history as the initial hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) to receive EU approval in August 2021, securing its position […]
Survey shows limited uptake with new anemia drugs
PHILADELPHIA — Results of a survey conducted in the U.S. and abroad showed that most nephrologists remain wary about prescribing hypoxia-inducible factor-prolyl hydroxylase inhibitors, according to a poster presentation at ASN Kidney Week. The survey was distributed to 207 U.S. and 208 European nephrologists practicing in Germany, Italy, France, Spain and the United Kingdom with […]
US Nephrologists Embrace Current IgA Nephropathy Therapies, Yet a Thriving Pipeline Signals Fierce Market Evolution Ahead
According to Spherix Global Insights, US nephrologists have expressed a high level of enthusiasm for Novartis’ iptacopan and atrasentan, as well as Otsuka’s sibeprenlimab, placing them at the forefront of their most anticipated products awaiting approval for the treatment of IgAN. Exton, Pa., October 13, 2023 – Innovation within the IgA nephropathy (IgAN) space continues […]
Akebia’s Vafseo (vadadustat) Poised to Make Waves for GSK’s Jesduvroq and FibroGen/Astellas’ Evrenzo
According to Spherix Global Insights and EU5 nephrologists are anticipating a more dynamic and competitive HIF-PH inhibitor market Exton, PA, July 20, 2023 – Nephrologists have long awaited the approval of HIF-PH inhibitors for the treatment of anemia in their chronic kidney disease (CKD) patients. While several agents within the class have found success globally, […]
Familiarity with GSK’s Jesduvroq® (daprodustat) Likely to Be Strong Driver of Adoption in Dialysis, According to Spherix Global Insights
According to Spherix Global Insights, the latest findings from RealTime Dynamix™: Renal Anemia report indicate that the more familiar nephrologists are with Jesduvroq, the more bullish they are about uptake. Exton, PA., March 27, 2023 – In the 32nd wave of ongoing tracking of the U.S. Renal Anemia market, Spherix surveyed 207 US nephrologists about […]
